Emerging Role of mTOR in the Response to Cancer Therapeutics

Trends in Cancer

Volumn 2, Issue 5, 2016, Pages 241-251

  Ilagan, Erika ^a   Manning, Brendan D ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR;

BREAST CANCER; CANCER THERAPY; HUMAN; LUNG CANCER; MELANOMA; MOLECULARLY TARGETED THERAPY; MUTANT; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

EID: 84968719169     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2016.03.008     Document Type: Review

References (91)

1. L.A. Garraway, and P.A. Janne Circumventing cancer drug resistance in the era of personalized medicine Cancer Discov. 2 2012 214 226
2. C.C. Dibble, and B.D. Manning Signal integration by mTORC1 coordinates nutrient input with biosynthetic output Nat. Cell Biol. 15 2013 555 564
3. A.M. Robitaille, and et al. Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis Science 339 2013 1320 1323
4. I. Ben-Sahra, and et al. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1 Science 339 2013 1323 1328
5. K. Duvel, and et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1 Mol. Cell 39 2010 171 183
6. T. Porstmann, and et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth Cell Metab. 8 2008 224 236
7. S.J.H. Ricoult, and et al. Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP Oncogene 35 2015 1250 1260
8. Jessica J. Howell, and et al. A growing role for mTOR in promoting anabolic metabolism Biochem. Soc. Trans. 41 2013 906 912
9. I. Ben-Sahra, and et al. mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle Science 351 2016 728 733
10. C.C. Dibble, and L.C. Cantley Regulation of mTORC1 by PI3K signaling Trends Cell Biol. 25 2015 545 555
11. L. Bar-Peled, and D.M. Sabatini Regulation of mTORC1 by amino acids Trends Cell Biol. 24 2014 400 406
12. Y. Sancak, and et al. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids Cell 141 2010 290 303
13. S. Menon, and et al. Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome Cell 156 2014 771 785
14. B.D. Manning, and et al. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/Akt pathway Mol. Cell 10 2002 151 162
15. K. Inoki, and et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling Nat. Cell Biol. 4 2002 648 657
16. A.R. Tee, and et al. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling Proc. Natl. Acad. Sci. U.S.A. 99 2002 13571 13576
17. P.P. Roux, and et al. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase Proc. Natl. Acad. Sci. U.S.A. 101 2004 13489 13494
18. L. Ma, and et al. Phosphorylation and functional inactivation of TSC2 by Erk Cell 121 2005 179 193
19. S. Menon, and B.D. Manning Common corruption of the mTOR signaling network in human tumors Oncogene 27 Suppl. 2 2008 S43 S51
20. F. Chiarini, and et al. Current treatment strategies for inhibiting mTOR in cancer Trends Pharmacol. Sci. 36 2015 124 135
21. J.J. Bissler, and et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis N. Engl. J. Med. 358 2008 140 151
22. D.N. Franz, and et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex Ann. Neurol. 59 2006 490 498
23. D.A. Krueger, and et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis N. Engl. J. Med. 363 2010 1801 1811
24. G. Iyer, and et al. Genome sequencing identifies a basis for everolimus sensitivity Science 338 2012 221
25. N. Wagle, and et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer N. Engl. J. Med. 371 2014 1426 1433
26. B.C. Grabiner, and et al. A diverse array of cancer-associated mTOR mutations are hyperactivating and can predict rapamycin sensitivity Cancer Discov. 4 2014 554 563
27. N. Wagle, and et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib Cancer Discov. 4 2014 546 553
28. J. Li, and et al. Rapamycin: one drug, many effects Cell Metab. 19 2014 373 379
29. J. Heitman, and et al. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast Science 253 1991 905 909
30. K.N. Pollizzi, and J.D. Powell Regulation of T cells by mTOR: the known knowns and the known unknowns Trends Immunol. 36 2015 13 20
31. L.S. Harrington, and et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins J. Cell Biol. 166 2004 213 223
32. O.J. Shah, and et al. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies Curr. Biol. 14 2004 1650 1656
33. B.D. Manning Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis J. Cell Biol. 167 2004 399 403
34. K.E. O'Reilly, and et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res. 66 2006 1500 1508
35. B.D. Manning, and L.C. Cantley AKT/PKB signaling: navigating downstream Cell 129 2007 1261 1274
36. C.C. Dibble, and et al. Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1 Mol. Cell. Biol. 29 2009 5657 5670
37. P.P. Hsu, and et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling Science 332 2011 1317 1322
38. Y. Yu, and et al. Quantitative phosphoproteomic analysis identifies the adaptor protein Grb10 as an mTORC1 substrate that negatively regulates insulin signaling Science 332 2011 1322 1326
39. V.S. Rodrik-Outmezguine, and et al. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling Cancer Discov. 1 2011 248 259
40. I. Kelsey, and B.D. Manning mTORC1 status dictates tumor response to targeted therapeutics Sci. Signal. 6 2013 pe31
41. C.R. Chong, and P.A. Janne The quest to overcome resistance to EGFR-targeted therapies in cancer Nat. Med. 19 2013 1389 1400
42. F. Ciardiello, and G. Tortora EGFR antagonists in cancer treatment N. Engl. J. Med. 358 2008 1160 1174
43. S.V. Sharma, and et al. Epidermal growth factor receptor mutations in lung cancer Nat. Rev. Cancer 7 2007 169 181
44. S. Kobayashi, and et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 352 2005 786 792
45. W. Pao, and et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med. 2 2005 0225 0235
46. E.L. Kwak, and et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib Proc. Natl. Acad. Sci. U.S.A. 102 2005 7665 7670
47. W. Zhou, and et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Nature 462 2009 1070 1074
48. A.O. Walter, and et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC Cancer Discov. 3 2013 1404 1415
49. D.A.E. Cross, and et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer Cancer Discov. 4 2014 1046 1061
50. J.A. Engelman, and et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines Proc. Natl. Acad. Sci. U.S.A. 102 2005 3788 3793
51. D.L. Wheeler, and et al. Understanding resistance to EGFR inhibitors-impact on future treatment strategies Nat. Rev. Clin. Oncol. 7 2010 493 507
52. E.M. Tricker, and et al. Combined EGFR/MEK inhibition prevents the emergence of resistance in EGFR-mutant lung cancer Cancer Discov. 5 2015 960 971
53. D. Li, and et al. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy Cancer Cell 12 2007 81 93
54. L. Regales, and et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer J. Clin. Invest. 119 2009 3000 3010
55. Y.Y. Janjigian, and et al. Dual Inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations Cancer Discov. 4 2014 1036 1045
56. V. Pirazzoli, and et al. Afatinib plus cetuximab delays resistance compared to single-agent erlotinib or afatinib in mouse models of TKI-naïve EGFR L858R-induced lung adenocarcinoma Clin. Cancer Res. 22 2016 426 435
57. V. Pirazzoli, and et al. Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1 Cell Rep. 7 2014 999 1008
58. S. Kawabata, and et al. Rapamycin prevents the development and progression of mutant EGFR lung tumors with the acquired resistance mutation T790M Cell Rep. 7 2014 1824 1832
59. H. Ebi, and et al. PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1 Proc. Natl. Acad. Sci. U.S.A. 110 2013 21124 21129
60. T.L. Yuan, and L.C. Cantley PI3K pathway alterations in cancer: variations on a theme Oncogene 27 2008 5497 5510
61. J.A. Engelman Targeting PI3K signalling in cancer: opportunities, challenges and limitations Nat. Rev. Cancer 9 2009 550 562
62. D. Juric, and et al. Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: preliminary safety, PK, and efficacy results from the first-in-human study Cancer Res 72 2012 CT-01-CT-01
63. C. Fritsch, and et al. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials Mol. Cancer Ther. 13 2014 1117 1129
64. M. Elkabets, and et al. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer Sci. Transl. Med. 5 2013 196ra199
65. H. Davies, and et al. Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
66. A.K.S. Salama, and K.T. Flaherty BRAF in melanoma: current strategies and future directions Clin. Cancer Res. 19 2013 4326 4334
67. M. Holderfield, and et al. Targeting RAF kinases for cancer therapy: BRAF mutated melanoma and beyond Nat. Rev. Cancer 14 2014 455 467
68. K.T. Flaherty, and et al. Improved survival with MEK inhibition in BRAF-mutated melanoma N. Engl. J. Med. 367 2012 107 114
69. P.B. Chapman, and et al. improved survival with vemurafenib in melanoma with BRAF V600E mutation N. Engl. J. Med. 364 2011 2507 2516
70. A. Hauschild, and et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Lancet 380 2012 358 365
71. R.B. Corcoran, and et al. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma Sci. Transl. Med 5 2013 196ra198
72. O. Maertens, and et al. Elucidating distinct roles for NF1 in melanomagenesis Cancer Discov. 3 2013 338 349
73. M. Elkabets, and et al. AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas Cancer Cell 27 2015 533 546
74. M.J. Niederst, and J.A. Engelman Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer Sci. Signal. 6 2013 1 6
75. L. Bar-Peled, and et al. A tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1 Science 340 2013 1100 1106
76. J. Okosun, and et al. Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma Nat. Genet. 48 2016 183 188
77. K.J. Lastwika, and et al. Control of PD-L1 expression by oncogenic activation of the AKT/mTOR pathway in non-small cell lung cancer Cancer Res. 76 2015 227 238
78. S. Wullschleger, and et al. TOR signaling in growth and metabolism Cell 124 2006 471 484
79. M. Laplante, and D.M. Sabatini mTOR signaling in growth control and disease Cell 149 2012 274 293
80. D.D. Sarbassov, and et al. Phosphorylation and regulation of Akt/PKB by the Rictor-mTOR Complex Science 307 2005 1098 1101
81. J.M. García-Martínez, and D.R. Alessi mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1) Biochem. J. 416 2008 375 385
82. V. Facchinetti, and et al. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C EMBO J. 27 2008 1932 1943
83. T. Ikenoue, and et al. Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling EMBO J. 27 2008 1919 1931
84. D.A. Guertin, and D.M. Sabatini The pharmacology of mTOR inhibition Sci. Signal. 2 2009 pe24
85. D. Benjamin, and et al. Rapamycin passes the torch: a new generation of mTOR inhibitors Nat. Rev. Drug Discov. 10 2011 868 880
86. D.D. Sarbassov, and et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB Mol. Cell 22 2006 159 168
87. A.Y. Choo, and et al. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation Proc. Natl. Acad. Sci.U.S.A. 105 2008 17414 17419
88. C.C. Thoreen, and et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1 J. Biol. Chem. 284 2009 8023 8032
89. M.E. Feldman, and et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2 PLoS Biol. 7 2009 0371 0383
90. S.A. Kang, and et al. mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin Science 341 2013 1236566
91. Q. Liu, and et al. Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics J. Biol. Chem. 287 2012 9742 9752